MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.124.268425

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025

A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.

Gillett Daniel, Senanayake Russell, MacFarlane James, Bashari Waiel, Palma August, Hu Lihua, Harper Ines, Mendichovszky Iosif A, Antoni Gunnar, Hellman Per, Sundin Anders, Hird Matthew, Boros István, Brown Morris J, Cheow Heok, Aloj Luigi, Aigbirhio Franklin, Gurnell Mark

СтатьяКлиническое исследование I фазыКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Primary aldosteronism (PA) is a common, potentially reversible, cause of hypertension. Distinguishing unilateral from bilateral PA is critical when deciding who should be offered surgery (unilateral adrenalectomy). Recent studies have shown that PET/CT with [11C]metomidate can accurately identify unilateral PA, with localization of the causative aldosterone-producing adenoma (APA). However, the availability of [11C]metomidate is limited to centers with an on-site cyclotron. Here, we report an early-phase human study with the 18F-labeled analog, para-chloro-2-[18F]fluoroethyletomidate ([18F]CETO).

Methods

We conducted a phase I/IIa, single-center, open-label, microdosing study. The primary objective was to evaluate the safety of up to 2 administrations of [18F]CETO in 6 patients with PA (3 unilateral disease, 3 bilateral disease) and 5 healthy volunteers. Safety evaluation included assessment of adrenal function after the first [18F]CETO administration. The biodistribution of [18F]CETO was assessed in a 90-min dynamic PET acquisition. In patients with PA, the effect of pretreatment with oral dexamethasone on [18F]CETO uptake by normal adrenal tissue and APAs was also assessed.

Results

Eleven participants were recruited to the trial, including 6 patients and 5 healthy volunteers. No subjects experienced serious adverse events or reactions, and all participants had normal adrenal function after [18F]CETO administration. [18F]CETO demonstrated high selectivity for the adrenal glands with low uptake in other tissues. Visualization of APAs was enhanced after dexamethasone pretreatment, which suppressed [18F]CETO uptake by normal adrenal tissue.

Conclusion

[18F]CETO is a safe radiopharmaceutical for PET imaging of the adrenal glands, with no observed adverse reactions or impairment of adrenal function in this study. [18F]CETO demonstrates selective high affinity for adrenal tissue, particularly APAs. Distinction between APAs and normal adrenal tissue is enhanced by dexamethasone pretreatment to suppress [18F]CETO uptake by normal glands. This positions [18F]CETO as a promising imaging tool for evaluation in the context of PA.

Для цитирования: Gillett Daniel, Senanayake Russell, MacFarlane James, Bashari Waiel, Palma August, Hu Lihua, Harper Ines, Mendichovszky Iosif A, Antoni Gunnar, Hellman Per, Sundin Anders, Hird Matthew, Boros István, Brown Morris J, Cheow Heok, Aloj Luigi, Aigbirhio Franklin, Gurnell Mark. A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. DOI: 10.2967/jnumed.124.268425.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.